Vivere Life Limited
UK-based personalized health and longevity startup offering AI-powered gut microbiome testing and NAD+ injection pens.
Website: https://www.viverelife.co.uk/
Cover Block
| Attribute | Detail |
|---|---|
| Name | Vivere Life Limited (trading as Vivere) |
| Tagline | UK-based personalized health and longevity startup offering AI-powered gut microbiome testing and NAD+ injection pens. |
| Headquarters | Nottingham, United Kingdom |
| Founded | 2024 |
| Business Model | Direct-to-Consumer (DTC) |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Western Europe |
Links
- Website: https://www.viverelife.co.uk/
- LinkedIn: https://www.linkedin.com/company/vivere-life/
- Companies House: https://find-and-update.company-information.service.gov.uk/company/15899819
- Trustpilot: https://uk.trustpilot.com/review/viverelife.co.uk
What an Investor Needs First
Vivere Life Limited is a UK-based healthtech startup offering personalized longevity services, combining high-resolution gut microbiome testing with pharmaceutical-grade NAD+ therapy. Founded in August 2024, the company operates a direct-to-consumer e-commerce platform [Companies House]. Its core product is an at-home gut microbiome test kit using shotgun metagenomic sequencing, paired with an AI-powered dashboard for personalized nutrition and lifestyle recommendations [viverelife.co.uk]. This diagnostic service is complemented by the sale of NAD+ injection pens, creating a potential dual revenue stream from testing and recurring refill kits.
The only named officer is Paul Cartwright, listed as the Data Protection Officer [viverelife.co.uk]. No external funding rounds, investors, or valuation have been disclosed. Services are restricted to UK residents aged 18 and over [viverelife.co.uk]. Over the next 12-18 months, key monitors will be the company's ability to translate its premium pricing,the gut test kit retails at £263.99 on promotion,into sustainable customer acquisition and repeat purchase rates [viverelife.co.uk].
Data Accuracy: YELLOW -- Core product claims and corporate status are confirmed by primary sources; team and funding details are absent.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Business Model | Direct-to-Consumer (DTC) |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Western Europe |
Inside the Company
Vivere Life Limited is a private UK company that began formal operations in August 2024. The company was incorporated on 15 August 2024 under company number 15899819, with its registered office in Nottingham and a listed business activity of "Other human health activities" [Companies House]. Its public-facing brand, Vivere, markets itself as "the UK’s leader in gut testing, NAD+ therapy & biohacking" [viverelife.co.uk].
The company launched its direct-to-consumer e-commerce platform, offering an at-home gut microbiome test kit and a pharmaceutical-grade NAD+ injection pen. A Trustpilot profile for customer reviews was active by at least February 2026 [Trustpilot, February 2026]. Services are restricted to users aged 18 and over with a UK shipping address [viverelife.co.uk]. Public records list Paul Cartwright as the company's Data Protection Officer [viverelife.co.uk].
Data Accuracy: YELLOW -- Company details confirmed via Companies House; product and operational claims are from the company's own website and policies.
Under the Hood
Vivere's product suite is a direct-to-consumer bundle of diagnostics and therapeutics, anchored by a high-resolution gut microbiome test and a pharmaceutical-grade NAD+ injection pen. The company's primary offering is an at-home test kit that uses shotgun metagenomic sequencing, a method that provides more detailed genetic analysis of gut bacteria than the 16S rRNA sequencing common in earlier consumer tests [viverelife.co.uk]. This core diagnostic is packaged with a 45-minute consultation with a nutritionist and a personalized online dashboard that delivers AI-powered nutrition and lifestyle recommendations, priced at £263.99 (promotional) for a bundle the company values at over £420 [viverelife.co.uk]. The second pillar is a longevity-focused therapeutic: a self-administered NAD+ injection pen, sold with refill kits [viverelife.co.uk]. A wellness e-commerce shop sells both Vivere-branded and third-party supplements [viverelife.co.uk].
Data Accuracy: YELLOW -- Product details and pricing are confirmed from the company website. The AI and sequencing technology claims are described by the company but lack independent technical verification.
Market Research
The consumer health and longevity market is shifting from generalized wellness advice to data-driven, personalized interventions. According to a Grand View Research report, the global at-home testing market size was valued at $20.7 billion in 2023 and is projected to expand at a compound annual growth rate of 7.9% from 2024 to 2030 [Grand View Research, 2024]. The global probiotics market is estimated at $61.9 billion in 2022 and is forecast to reach $95.9 billion by 2030 [Allied Market Research, 2023].
Data Accuracy: YELLOW -- Market sizing is based on analogous, third-party industry reports for broader categories.
Competition and Substitutes
Vivere Life enters a fragmented wellness market by bundling high-resolution gut microbiome analysis with a pharmaceutical-grade longevity product. The competitive map for consumer health testing and biohacking in the UK includes companies like Zoe (US/UK) and Atlas Biomed (UK) in the gut microbiome testing space. The NAD+ and longevity supplement segment is served by online pharmacies, specialized clinics, and direct-to-consumer brands like Elevant and AgelessRx. General wellness and supplement e-commerce is dominated by retailers like Holland & Barrett and Boots.
Data Accuracy: YELLOW -- Landscape analysis is inferred from public market descriptions.
Opportunity
The opportunity for Vivere Life is to become the UK's integrated platform for personalized longevity interventions. The integration of a diagnostic test with a subsequent therapeutic product creates a potential high-margin cross-sell path [viverelife.co.uk].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Vertical Integration into Supplementation | Vivere uses gut test data to drive automated, high-margin sales of its own branded supplement lines. | Launch of proprietary, data-informed supplement formulations. | The company already operates a wellness shop and provides personalized product suggestions [viverelife.co.uk]. |
| B2B2C Partnership Model | The testing and recommendation platform is white-labeled or offered as a benefit through corporate wellness programs. | Securing a pilot partnership with a UK-based wellness provider. | The product's at-home, digital-first delivery model is inherently scalable. |
| Portfolio Expansion via New Biomarkers | The company layers additional at-home tests onto its existing customer base and dashboard. | Introduction of a second proprietary test kit. | Success with the initial gut test creates a captive audience for additional diagnostic products. |
Data Accuracy: YELLOW -- Product and market positioning are confirmed by the company's website. Growth scenarios are extrapolated from the company's current model.
Sources
- [Companies House] Vivere Life Limited - Company number 15899819 | https://find-and-update.company-information.service.gov.uk/company/15899819
- [viverelife.co.uk] Vivere: UK's Leader in Gut Testing, NAD+ Therapy & Biohacking | https://www.viverelife.co.uk/
- [Trustpilot, February 2026] Vivere Reviews | Read Customer Service Reviews of viverelife.co.uk | https://uk.trustpilot.com/review/viverelife.co.uk
- [Trustpilot, March 2026] Vivere Reviews | Read Customer Service Reviews of viverelife.co.uk | https://uk.trustpilot.com/review/viverelife.co.uk
Articles about Vivere Life Limited
- Vivere Life's £264 Gut Test Puts Shotgun Sequencing Into UK Homes — The Nottingham startup combines high-resolution microbiome analysis with AI recommendations and NAD+ pens, betting on a direct-to-consumer longevity market.